GNPX - Genprex, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
10.10
+0.04 (+0.40%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close10.06
Open10.00
Bid9.80 x 3200
Ask10.15 x 800
Day's Range10.00 - 10.26
52 Week Range3.84 - 19.45
Volume23,797
Avg. Volume468,810
Market Cap140.021M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.29
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Genprex Selects Accenture To Support Acceleration Of Oncoprex Clinical Development Program
    PR Newswire14 days ago

    Genprex Selects Accenture To Support Acceleration Of Oncoprex Clinical Development Program

    AUSTIN, Texas and CAMBRIDGE, Mass., May 8, 2018 /PRNewswire/ -- Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has selected Accenture to provide clinical data management services to help accelerate the clinical development of Genprex's lead drug candidate, Oncoprex™, for the treatment of non-small cell lung cancer (NSCLC). Under the agreement, Accenture, a leading global professional services company, is supporting Genprex with clinical data management and submission-compliant CDISC deliverable activities for the Phase I/II clinical trial combining Genprex's Oncoprex and the EGFR-inhibitor erlotinib (Tarceva®) in stage IV lung cancer.  Accenture's Clinical Data Management team has executed thousands of clinical trials in a variety of therapeutic areas, supported by experienced industry professionals who understand the importance of a standards-fueled, data-centric approach across each phase of drug development.

  • Genprex To Present At 2018 Disruptive Growth & Healthcare Conference
    PR Newswire15 days ago

    Genprex To Present At 2018 Disruptive Growth & Healthcare Conference

    AUSTIN, Texas , May 7, 2018 /PRNewswire/ --  Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, ...

  • Genprex Announces $10 Million Private Placement
    PR Newswire15 days ago

    Genprex Announces $10 Million Private Placement

    AUSTIN, Texas, May 7, 2018 /PRNewswire/ -- Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has entered into definitive securities purchase agreements with institutional investors in connection with a private placement of $10.0 million of shares of its common stock and warrants. The per share purchase price of the common stock is equal to $12.07, and the initial exercise price for the warrants is equal to $15.62 per share. The warrants will be exercisable on the earlier of 6 months from the issuance date or the date of effectiveness of the registration statement registering the underlying shares for resale and will expire 5 years from such date.

  • ACCESSWIRE25 days ago

    Today’s Research Reports on Stocks to Watch: Genprex and Celgene

    Genprex also announced this week that it has established offices in Massachusetts to help accelerate the clinical development of Oncoprex, its lead immunogene therapy for non-small cell lung cancer. Shares of Celgene also saw gains after a report discussed that Juno Therapeutics' CEO quietly stepped down from his role and joined Celgene's board. The company also announced on Wednesday that it has established offices in Cambridge, Mass. to help accelerate the clinical development of its lead drug candidate, Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC).

  • ACCESSWIRE26 days ago

    Genprex, New IPO in Biotech Generates Investor Interest with Lung Cancer Program

    NEW YORK, NY / ACCESSWIRE / April 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • Genprex Joins The Health Discovery Building At Dell Medical School To Help Drive Innovation For Health And Life Sciences
    PR Newswirelast month

    Genprex Joins The Health Discovery Building At Dell Medical School To Help Drive Innovation For Health And Life Sciences

    AUSTIN, Texas, April 18, 2018 /PRNewswire/ -- Genprex, Inc., a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today that it has entered an agreement with The University of Texas at Austin Dell Medical School to establish executive offices at the school's Health Discovery Building, joining the WorkSpaces @ Texas Health CoLab that brings together value-focused health entrepreneurs and businesses to enable a robust health innovation ecosystem. "Texas Health CoLab combines world-class research and technology capabilities, along with passionate people and space for multi-disciplinary teamwork, and we're delighted to welcome Genprex to our collaborative space," said Dr. Ruben Rathnasingham, Managing Director of the Texas Health CoLab.

  • Genprex Provides Clinical and Corporate Update
    PR Newswirelast month

    Genprex Provides Clinical and Corporate Update

    Announced in January 2017 positive interim data from the Phase II portion of the ongoing Phase I/II clinical trial evaluating OncoprexTM in combination with the tyrosine kinase inhibitor (TKI) erlotinib (Tarceva®) for the treatment of late stage non-small cell lung cancer (NSCLC) patients, with and without EGFR mutations, who have failed at least two drug regimens.  Of the 39 patients allowed in the protocol for the Phase II portion of the trial, 10 have been enrolled and nine are evaluable under the trial protocol as they received two or more cycles of the treatment.

  • Genprex Appoints Julien Pham, MD, MPH As President To Lead Commercialization Of Oncoprex Immunogene Therapy
    PR Newswirelast month

    Genprex Appoints Julien Pham, MD, MPH As President To Lead Commercialization Of Oncoprex Immunogene Therapy

    AUSTIN, Texas and CAMBRIDGE, Mass., April 11, 2018 /PRNewswire/ -- Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of Julien L. Pham, MD, MPH as the Company's President. In this expanded senior management position, Dr. Pham, who joined Genprex in 2016 as Chief Operating Officer, will lead the Company's clinical development program as well as establish and grow strategic partnerships that contribute to Genprex's corporate objectives and innovative work across oncology and gene therapy.

  • ACCESSWIRElast month

    Genprex (GNPX) Stock: May Offer Significant Growth Opportunity

    This Research Originally Appeared on CNA Finance CORAL SPRINGS, FL / ACCESSWIRE / April 10, 2018 / Genprex, Inc. closed its IPO on April 3, 2018, selling 1.28 million shares of common stock at a price ...

  • Genprex Announces Pricing of Initial Public Offering of Common Stock
    PR Newswire2 months ago

    Genprex Announces Pricing of Initial Public Offering of Common Stock

    AUSTIN, Texas , March 29, 2018 /PRNewswire/ -- Genprex, Inc. , a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today the pricing of its initial ...